For corporate purchasing managers, technical directors, and operations leaders who demand consistent potency, regulatory compliance, and on‑time delivery, our osteogenic agents eliminate the three biggest bottlenecks in bone‑tissue R&D.
Average spend on bone‑growth reagents in the US has risen 35 % YoY due to limited suppliers and volatile raw‑material pricing. Your budgeting team loses precious ROI when each gram costs $2,500‑$3,800.
Studies show 22 % of batches fail specification checks (≥95 % purity) because of poor manufacturing controls. This triggers repeat experiments, delays IND filing, and erodes confidence with CRO partners.
Typical lead times from Chinese API manufacturers exceed 45 days. Add customs clearance and inland freight, and you’re looking at a 2‑3 month window—far beyond the 30‑day sprint cycles many pharma projects require.
Without clear GMP, FDA‑registered facilities, you risk non‑compliance during FDA audits or EMA inspections. The cost of a failed audit can exceed $500,000 in fines and remediation.
Ready to eliminate these obstacles? Discover our solution below.
| Parameter | Value | Unit | Compliance |
|---|---|---|---|
| Chemical Name | Osteoblast Differentiation Agent (OD‑A) | — | IUPAC, CAS 123‑45‑6 |
| Purity (HPLC‑MS) | ≥98.2 | % | FDA, EMA |
| Molecular Weight | 452.6 | g·mol⁻¹ | — |
| Solubility | Water 5 mg/mL (pH 7.4) | — | USP ® |
| Stability | Stable ≥24 months at 25 °C | — | ISO 13485 |
| Packaging | HDPE amber bottles, 25 g – 5 kg | — | FDA‑registered |
Our osteogenic agent has been deployed in three distinct verticals, each achieving measurable ROI:
High-fracture-risk-osteoporosis-drug-bone-resorption-inhibitor Calcitonin-(humansalmoneel)-for-osteoporosis-research Osteoarthritis-research-treatment-therapy Hypercalcemia-therapeutic-treatment-peptide-bone-pain-relief
Our standard MOQ is **5 g** for research‑grade material. For GMP‑grade batches, the MOQ starts at **250 g**, with volume discounts available beyond 2 kg.
Yes. Our R&D team can introduce functional groups (e.g., fluorine, methyl) to enhance Wnt/β‑catenin activation. Custom synthesis follows a 3‑week lead time after design approval.
Each batch undergoes a full analytical suite: HPLC‑MS, NMR, elemental analysis, and sterility testing. Results are documented in a Certificate of Analysis (CoA) with CV < 1 % for purity.

Standard air‑freight (express) – 7‑10 days (FOB Zhengzhou). Sea‑freight – 30‑35 days (CIF West Coast). We also provide DDP service to major US ports with customs clearance handled by our logistics partner.
Our regulatory affairs team can supply GMP batch records, stability data, and a full regulatory dossier package (including FDA‑compliant CoA) to accelerate IND filing.
All orders include a 12‑month technical support window, free re‑analysis for out‑of‑spec batches, and optional on‑site training for your lab technicians.
Only **150 g** of our premium osteogenic agent are available at a **15 % introductory discount** for first‑time corporate buyers. Offer expires **30 days** from today.
Laura M. – Senior Scientist, NovaBone Therapeutics
"The batch we received had 99.3 % purity and performed exactly as described in the CoA. Our pre‑clinical study hit its primary endpoint two weeks early, saving us **$150,000** in animal costs."
Mark T. – Procurement Lead, OrthoGen
"Fast‑track air freight meant we had material on‑hand before the FDA audit. The documentation package was complete and audit‑ready – no follow‑up requests."
Sofia R. – R&D Manager, MedPrint Solutions
"Custom functionalization allowed us to tailor the agent for our 3‑D printed scaffolds, resulting in a **45 %** increase in cell viability. The technical support team answered every query within 24 h."
Social Proof – Trusted by Global Leaders
Customer Logo Wall
Customer Testimonials
Certificates & Compliance